Shares of Defence Therapeutics Inc. (OTCMKTS:DTCFF – Get Free Report) rose 66.8% during trading on Friday . The company traded as high as $0.46 and last traded at $0.46. Approximately 3,358 shares changed hands during trading, an increase of 281% from the average daily volume of 882 shares. The stock had previously closed at $0.27.
Defence Therapeutics Price Performance
The company’s 50-day simple moving average is $0.39 and its two-hundred day simple moving average is $0.49.
Defence Therapeutics Company Profile
Defence Therapeutics Inc engages in development of a biological drug enhancer platform that improves the efficacy and safety of a multitude of biological/biosimilar based pharmaceuticals used in the treatment of cancer and infectious diseases. The company focuses on development of vaccine for infectious disease and virus utilizing the ACCUMTM platform for drug delivery and effective treatments.
See Also
- Five stocks we like better than Defence Therapeutics
- What is Short Interest? How to Use It
- S&P 500 ETFs: Expense Ratios That Can Boost Your Long-Term Gains
- P/E Ratio Calculation: How to Assess Stocks
- How AI Implementation Could Help MongoDB Roar Back in 2025
- Using the MarketBeat Dividend Yield Calculator
- Hedge Funds Boost Oil Positions: Is a Major Rally on the Horizon?
Receive News & Ratings for Defence Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Defence Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
